Condition: Gulf War Illness · Sponsor: Roskamp Institute Inc.
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
This description comes directly from the study's public registry record.
Dakota Helgager · 9412568019 · dhelgager@roskampclinic.org
Always discuss trial participation with your own doctor first.
| Nova Southeastern University | Fort Lauderdale, Florida, United States | Recruiting |
| The Roskamp Institute | Sarasota, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05243290